Skip to main content
Top
Published in: Diabetology & Metabolic Syndrome 1/2024

Open Access 01-12-2024 | Pregnancy Cholestasis | Research

Gestational diabetes mellitus aggravates adverse perinatal outcomes in women with intrahepatic cholestasis of pregnancy

Authors: Xia Li, Qin-Yu Cai, Xin Luo, Yong-Heng Wang, Li-Zhen Shao, Shu-Juan Luo, Lan Wang, Ying-Xiong Wang, Xia Lan, Tai-Hang Liu

Published in: Diabetology & Metabolic Syndrome | Issue 1/2024

Login to get access

Abstract

Purpose

To evaluate the effect of intrahepatic cholestasis of pregnancy (ICP) with gestational diabetes mellitus (GDM) on perinatal outcomes and establish a prediction model of adverse perinatal outcomes in women with ICP.

Methods

This multicenter retrospective cohort study included the clinical data of 2,178 pregnant women with ICP, including 1,788 women with ICP and 390 co-occurrence ICP and GDM. The data of all subjects were collected from hospital electronic medical records. Univariate and multivariate logistic regression analysis were used to compare the incidence of perinatal outcomes between ICP with GDM group and ICP alone group.

Results

Baseline characteristics of the population revealed that maternal age (p < 0.001), pregestational weight (p = 0.01), pre-pregnancy BMI (p < 0.001), gestational weight gain (p < 0.001), assisted reproductive technology (ART) (p < 0.001), and total bile acid concentration (p = 0.024) may be risk factors for ICP with GDM. Furthermore, ICP with GDM demonstrated a higher association with both polyhydramnios (OR 2.66) and preterm labor (OR 1.67) compared to ICP alone. Further subgroup analysis based on the severity of ICP showed that elevated total bile acid concentrations were closely associated with an increased risk of preterm labour, meconium-stained amniotic fluid, and low birth weight in both ICP alone and ICP with GDM groups. ICP with GDM further worsened these outcomes, especially in women with severe ICP. The nomogram prediction model effectively predicted the occurrence of preterm labour in the ICP population.

Conclusions

ICP with GDM may result in more adverse pregnancy outcomes, which are associated with bile acid concentrations.
Appendix
Available only for authorised users
Literature
1.
2.
go back to reference Kawakita T, Parikh LI, Ramsey PS, Huang C-C, Zeymo A, Fernandez M, et al. Predictors of adverse neonatal outcomes in intrahepatic cholestasis of pregnancy. Am J Obstet Gynecol. 2015;213:570e1–8.CrossRef Kawakita T, Parikh LI, Ramsey PS, Huang C-C, Zeymo A, Fernandez M, et al. Predictors of adverse neonatal outcomes in intrahepatic cholestasis of pregnancy. Am J Obstet Gynecol. 2015;213:570e1–8.CrossRef
3.
go back to reference Brouwers L, Koster MPH, Page-Christiaens GCML, Kemperman H, Boon J, Evers IM, et al. Intrahepatic cholestasis of pregnancy: maternal and fetal outcomes associated with elevated bile acid levels. Am J Obstet Gynecol. 2015;212:100e1–7.CrossRef Brouwers L, Koster MPH, Page-Christiaens GCML, Kemperman H, Boon J, Evers IM, et al. Intrahepatic cholestasis of pregnancy: maternal and fetal outcomes associated with elevated bile acid levels. Am J Obstet Gynecol. 2015;212:100e1–7.CrossRef
4.
go back to reference Ovadia C, Seed PT, Sklavounos A, Geenes V, Di Ilio C, Chambers J, et al. Association of adverse perinatal outcomes of intrahepatic cholestasis of pregnancy with biochemical markers: results of aggregate and individual patient data meta-analyses. Lancet Lond Engl. 2019;393:899–909.CrossRef Ovadia C, Seed PT, Sklavounos A, Geenes V, Di Ilio C, Chambers J, et al. Association of adverse perinatal outcomes of intrahepatic cholestasis of pregnancy with biochemical markers: results of aggregate and individual patient data meta-analyses. Lancet Lond Engl. 2019;393:899–909.CrossRef
5.
go back to reference Glantz A, Marschall H-U, Mattsson L-A. Intrahepatic cholestasis of pregnancy: relationships between bile acid levels and fetal complication rates. Hepatol Baltim Md. 2004;40:467–74.CrossRef Glantz A, Marschall H-U, Mattsson L-A. Intrahepatic cholestasis of pregnancy: relationships between bile acid levels and fetal complication rates. Hepatol Baltim Md. 2004;40:467–74.CrossRef
6.
go back to reference International Association of Diabetes and Pregnancy Study Groups Consensus Panel, Metzger BE, Gabbe SG, Persson B, Buchanan TA, Catalano PA, et al. International association of diabetes and pregnancy study groups recommendations on the diagnosis and classification of hyperglycemia in pregnancy. Diabetes Care. 2010;33:676–82.CrossRefPubMedCentral International Association of Diabetes and Pregnancy Study Groups Consensus Panel, Metzger BE, Gabbe SG, Persson B, Buchanan TA, Catalano PA, et al. International association of diabetes and pregnancy study groups recommendations on the diagnosis and classification of hyperglycemia in pregnancy. Diabetes Care. 2010;33:676–82.CrossRefPubMedCentral
7.
go back to reference American Diabetes Association. Standards of medical care in diabetes–2011. Diabetes Care. 2011;34(Suppl 1):11–61.CrossRef American Diabetes Association. Standards of medical care in diabetes–2011. Diabetes Care. 2011;34(Suppl 1):11–61.CrossRef
9.
go back to reference Wikström Shemer E, Marschall HU, Ludvigsson JF, Stephansson O. Intrahepatic cholestasis of pregnancy and associated adverse pregnancy and fetal outcomes: a 12-year population-based cohort study. BJOG Int J Obstet Gynaecol. 2013;120:717–23.CrossRef Wikström Shemer E, Marschall HU, Ludvigsson JF, Stephansson O. Intrahepatic cholestasis of pregnancy and associated adverse pregnancy and fetal outcomes: a 12-year population-based cohort study. BJOG Int J Obstet Gynaecol. 2013;120:717–23.CrossRef
10.
go back to reference Tomkin GH, Owens D. Obesity diabetes and the role of bile acids in metabolism. J Transl Intern Med. 2016;4:73–80.CrossRef Tomkin GH, Owens D. Obesity diabetes and the role of bile acids in metabolism. J Transl Intern Med. 2016;4:73–80.CrossRef
11.
go back to reference Pineda Torra I, Claudel T, Duval C, Kosykh V, Fruchart J-C, Staels B. Bile acids induce the expression of the human peroxisome proliferator-activated receptor alpha gene via activation of the farnesoid X receptor. Mol Endocrinol Baltim Md. 2003;17:259–72.CrossRef Pineda Torra I, Claudel T, Duval C, Kosykh V, Fruchart J-C, Staels B. Bile acids induce the expression of the human peroxisome proliferator-activated receptor alpha gene via activation of the farnesoid X receptor. Mol Endocrinol Baltim Md. 2003;17:259–72.CrossRef
13.
go back to reference Zhang Y, Lee FY, Barrera G, Lee H, Vales C, Gonzalez FJ, et al. Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice. Proc Natl Acad Sci U S A. 2006;103:1006–11.ADSCrossRefPubMedPubMedCentral Zhang Y, Lee FY, Barrera G, Lee H, Vales C, Gonzalez FJ, et al. Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice. Proc Natl Acad Sci U S A. 2006;103:1006–11.ADSCrossRefPubMedPubMedCentral
14.
go back to reference Wu K, Yin B, Li S, Zhu X, Zhu B. Prevalence, risk factors and adverse perinatal outcomes for Chinese women with intrahepatic cholestasis of pregnancy: a large cross-sectional retrospective study. Ann Med. 2022;54:2966–74.CrossRefPubMedPubMedCentral Wu K, Yin B, Li S, Zhu X, Zhu B. Prevalence, risk factors and adverse perinatal outcomes for Chinese women with intrahepatic cholestasis of pregnancy: a large cross-sectional retrospective study. Ann Med. 2022;54:2966–74.CrossRefPubMedPubMedCentral
15.
go back to reference Lee RH, Kwok KM, Ingles S, Wilson ML, Mullin P, Incerpi M, et al. Pregnancy outcomes during an era of aggressive management for intrahepatic cholestasis of pregnancy. Am J Perinatol. 2008;25:341–5.CrossRefPubMed Lee RH, Kwok KM, Ingles S, Wilson ML, Mullin P, Incerpi M, et al. Pregnancy outcomes during an era of aggressive management for intrahepatic cholestasis of pregnancy. Am J Perinatol. 2008;25:341–5.CrossRefPubMed
16.
go back to reference Society for Maternal-Fetal Medicine (SMFM). Electronic address: pubs@smfm.org, Lee RH, Mara Greenberg null, Metz TD, Pettker CM. Society for Maternal-Fetal Medicine Consult Series #53: Intrahepatic cholestasis of pregnancy: Replaces Consult #13, April 2011. Am J Obstet Gynecol. 2021;224:B2–9. Society for Maternal-Fetal Medicine (SMFM). Electronic address: pubs@smfm.org, Lee RH, Mara Greenberg null, Metz TD, Pettker CM. Society for Maternal-Fetal Medicine Consult Series #53: Intrahepatic cholestasis of pregnancy: Replaces Consult #13, April 2011. Am J Obstet Gynecol. 2021;224:B2–9.
17.
go back to reference Sarker M, Zamudio AR, DeBolt C, Ferrara L. Beyond stillbirth: association of intrahepatic cholestasis of pregnancy severity and adverse outcomes. Am J Obstet Gynecol. 2022;227:517.e1-517.e7. Sarker M, Zamudio AR, DeBolt C, Ferrara L. Beyond stillbirth: association of intrahepatic cholestasis of pregnancy severity and adverse outcomes. Am J Obstet Gynecol. 2022;227:517.e1-517.e7.
18.
go back to reference Geenes V, Chappell LC, Seed PT, Steer PJ, Knight M, Williamson C. Association of severe intrahepatic cholestasis of pregnancy with adverse pregnancy outcomes: a prospective population-based case-control study. Hepatol Baltim Md. 2014;59:1482–91.CrossRef Geenes V, Chappell LC, Seed PT, Steer PJ, Knight M, Williamson C. Association of severe intrahepatic cholestasis of pregnancy with adverse pregnancy outcomes: a prospective population-based case-control study. Hepatol Baltim Md. 2014;59:1482–91.CrossRef
20.
go back to reference Horgan R, Bitas C, Abuhamad A. Intrahepatic cholestasis of pregnancy: a comparison of Society for Maternal-Fetal Medicine and the Royal College of Obstetricians and gynaecologists’ guidelines. Am J Obstet Gynecol MFM. 2022;5:100838.CrossRefPubMed Horgan R, Bitas C, Abuhamad A. Intrahepatic cholestasis of pregnancy: a comparison of Society for Maternal-Fetal Medicine and the Royal College of Obstetricians and gynaecologists’ guidelines. Am J Obstet Gynecol MFM. 2022;5:100838.CrossRefPubMed
21.
go back to reference Axelsen SM, Kampmann U, Koefoed AS, McIntyre D, Ovesen PG, Fuglsang J. Intrahepatic cholestasis of pregnancy: Association with glycaemic control in gestational diabetes. Diabet Med J Br Diabet Assoc. 2021;38:e14574.CrossRef Axelsen SM, Kampmann U, Koefoed AS, McIntyre D, Ovesen PG, Fuglsang J. Intrahepatic cholestasis of pregnancy: Association with glycaemic control in gestational diabetes. Diabet Med J Br Diabet Assoc. 2021;38:e14574.CrossRef
22.
go back to reference Liu C, Gao J, Liu J, Wang X, He J, Sun J, et al. Intrahepatic cholestasis of pregnancy is associated with an increased risk of gestational diabetes and preeclampsia. Ann Transl Med. 2020;8:1574.CrossRefPubMedPubMedCentral Liu C, Gao J, Liu J, Wang X, He J, Sun J, et al. Intrahepatic cholestasis of pregnancy is associated with an increased risk of gestational diabetes and preeclampsia. Ann Transl Med. 2020;8:1574.CrossRefPubMedPubMedCentral
23.
go back to reference Martineau M, Raker C, Powrie R, Williamson C. Intrahepatic cholestasis of pregnancy is associated with an increased risk of gestational diabetes. Eur J Obstet Gynecol Reprod Biol. 2014;176:80–5.CrossRefPubMed Martineau M, Raker C, Powrie R, Williamson C. Intrahepatic cholestasis of pregnancy is associated with an increased risk of gestational diabetes. Eur J Obstet Gynecol Reprod Biol. 2014;176:80–5.CrossRefPubMed
24.
go back to reference Majewska A, Godek B, Bomba-Opon D, Wielgos M. Association between intrahepatic cholestasis in pregnancy and gestational diabetes mellitus. A retrospective analysis. Ginekol Pol. 2019;90:458–63.CrossRefPubMed Majewska A, Godek B, Bomba-Opon D, Wielgos M. Association between intrahepatic cholestasis in pregnancy and gestational diabetes mellitus. A retrospective analysis. Ginekol Pol. 2019;90:458–63.CrossRefPubMed
26.
go back to reference Van Mil SWC, Milona A, Dixon PH, Mullenbach R, Geenes VL, Chambers J, et al. Functional variants of the central bile acid sensor FXR identified in intrahepatic cholestasis of pregnancy. Gastroenterology. 2007;133:507–16.CrossRefPubMed Van Mil SWC, Milona A, Dixon PH, Mullenbach R, Geenes VL, Chambers J, et al. Functional variants of the central bile acid sensor FXR identified in intrahepatic cholestasis of pregnancy. Gastroenterology. 2007;133:507–16.CrossRefPubMed
27.
go back to reference Mitchell AL, Ovadia C, Syngelaki A, Souretis K, Martineau M, Girling J, et al. Re-evaluating diagnostic thresholds for intrahepatic cholestasis of pregnancy: case-control and cohort study. BJOG Int J Obstet Gynaecol. 2021;128:1635–44.CrossRef Mitchell AL, Ovadia C, Syngelaki A, Souretis K, Martineau M, Girling J, et al. Re-evaluating diagnostic thresholds for intrahepatic cholestasis of pregnancy: case-control and cohort study. BJOG Int J Obstet Gynaecol. 2021;128:1635–44.CrossRef
28.
go back to reference Liu L, Oza S, Hogan D, Perin J, Rudan I, Lawn JE, et al. Global, regional, and national causes of child mortality in 2000-13, with projections to inform post-2015 priorities: an updated systematic analysis. Lancet Lond Engl. 2015;385:430–40.CrossRef Liu L, Oza S, Hogan D, Perin J, Rudan I, Lawn JE, et al. Global, regional, and national causes of child mortality in 2000-13, with projections to inform post-2015 priorities: an updated systematic analysis. Lancet Lond Engl. 2015;385:430–40.CrossRef
29.
go back to reference Saigal S, Doyle LW. An overview of mortality and sequelae of preterm birth from infancy to adulthood. Lancet Lond Engl. 2008;371:261–9.CrossRef Saigal S, Doyle LW. An overview of mortality and sequelae of preterm birth from infancy to adulthood. Lancet Lond Engl. 2008;371:261–9.CrossRef
30.
go back to reference Vogel JP, Oladapo OT, Manu A, Gülmezoglu AM, Bahl R. New WHO recommendations to improve the outcomes of preterm birth. Lancet Glob Health. 2015;3:e589–590.CrossRefPubMed Vogel JP, Oladapo OT, Manu A, Gülmezoglu AM, Bahl R. New WHO recommendations to improve the outcomes of preterm birth. Lancet Glob Health. 2015;3:e589–590.CrossRefPubMed
31.
go back to reference Sun Q, Zou X, Yan Y, Zhang H, Wang S, Gao Y, et al. Machine learning-based prediction model of Preterm Birth using Electronic Health Record. J Healthc Eng. 2022;2022:9635526.CrossRefPubMedPubMedCentral Sun Q, Zou X, Yan Y, Zhang H, Wang S, Gao Y, et al. Machine learning-based prediction model of Preterm Birth using Electronic Health Record. J Healthc Eng. 2022;2022:9635526.CrossRefPubMedPubMedCentral
32.
go back to reference Tarca AL, Pataki BÁ, Romero R, Sirota M, Guan Y, Kutum R, et al. Crowdsourcing assessment of maternal blood multi-omics for predicting gestational age and preterm birth. Cell Rep Med. 2021;2:100323.CrossRefPubMedPubMedCentral Tarca AL, Pataki BÁ, Romero R, Sirota M, Guan Y, Kutum R, et al. Crowdsourcing assessment of maternal blood multi-omics for predicting gestational age and preterm birth. Cell Rep Med. 2021;2:100323.CrossRefPubMedPubMedCentral
33.
go back to reference Stock SJ, Horne M, Bruijn M, White H, Boyd KA, Heggie R, et al. Development and validation of a risk prediction model of preterm birth for women with preterm labour symptoms (the QUIDS study): a prospective cohort study and individual participant data meta-analysis. PLoS Med. 2021;18:e1003686.CrossRefPubMedPubMedCentral Stock SJ, Horne M, Bruijn M, White H, Boyd KA, Heggie R, et al. Development and validation of a risk prediction model of preterm birth for women with preterm labour symptoms (the QUIDS study): a prospective cohort study and individual participant data meta-analysis. PLoS Med. 2021;18:e1003686.CrossRefPubMedPubMedCentral
Metadata
Title
Gestational diabetes mellitus aggravates adverse perinatal outcomes in women with intrahepatic cholestasis of pregnancy
Authors
Xia Li
Qin-Yu Cai
Xin Luo
Yong-Heng Wang
Li-Zhen Shao
Shu-Juan Luo
Lan Wang
Ying-Xiong Wang
Xia Lan
Tai-Hang Liu
Publication date
01-12-2024
Publisher
BioMed Central
Published in
Diabetology & Metabolic Syndrome / Issue 1/2024
Electronic ISSN: 1758-5996
DOI
https://doi.org/10.1186/s13098-024-01294-z

Other articles of this Issue 1/2024

Diabetology & Metabolic Syndrome 1/2024 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.